Patent position of Merus’ MeMo® Mouse strengthened by ruling of European Patent Office
Posted on 18 September, 2014
In 2012, Regeneron was granted a European patent entitled “Methods of Modifying Eukaryotic Cells”. The patent is part of Regeneron’s IP portfolio around its VelocImmune® mouse for therapeutic human antibodies. Merus filed an opposition against this patent in June 2013, thereby requesting revocation of the patent.
“This outcome fully confirms our firm belief that we have freedom to operate for our MeMo® mice for common light chain therapeutic human antibodies,” said Ton Logtenberg, CEO of Merus. “The decision by the opposition division will allow for continued use in Europe of our MeMo® mice for the generation of bispecific antibodies (Biclonics®) for the treatment of cancer patients.”